Sera Prognostics, Inc. (NASDAQ:SERA) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its stake in shares of Sera Prognostics, Inc. (NASDAQ:SERA - Free Report) by 7,357.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 884,867 shares of the company's stock after purchasing an additional 873,002 shares during the period. JPMorgan Chase & Co. owned approximately 2.62% of Sera Prognostics worth $6,902,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Quest Partners LLC lifted its stake in shares of Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company's stock valued at $50,000 after purchasing an additional 5,415 shares in the last quarter. SG Americas Securities LLC acquired a new position in Sera Prognostics during the third quarter valued at approximately $78,000. The Manufacturers Life Insurance Company purchased a new stake in Sera Prognostics during the second quarter worth approximately $68,000. Prime Capital Investment Advisors LLC acquired a new stake in shares of Sera Prognostics in the third quarter worth $104,000. Finally, Jane Street Group LLC raised its stake in shares of Sera Prognostics by 24.8% in the 3rd quarter. Jane Street Group LLC now owns 14,225 shares of the company's stock valued at $111,000 after acquiring an additional 2,826 shares during the period. Institutional investors and hedge funds own 54.64% of the company's stock.

Sera Prognostics Stock Performance

Shares of NASDAQ:SERA traded down $0.01 during midday trading on Thursday, hitting $6.60. 86,681 shares of the company's stock traded hands, compared to its average volume of 130,378. Sera Prognostics, Inc. has a twelve month low of $4.98 and a twelve month high of $12.35. The company has a market cap of $222.88 million, a PE ratio of -6.67 and a beta of 0.86. The firm's fifty day moving average price is $7.40 and its two-hundred day moving average price is $7.31.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.09 million. During the same quarter in the previous year, the company posted ($0.23) EPS. As a group, equities research analysts anticipate that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Insiders Place Their Bets

In other Sera Prognostics news, Director Joshua Phillips sold 12,163 shares of the business's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $6.39, for a total value of $77,721.57. Following the transaction, the director now owns 2 shares in the company, valued at $12.78. The trade was a 99.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Paul Kearney sold 4,078 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $29,850.96. Following the completion of the transaction, the insider now directly owns 176,889 shares of the company's stock, valued at approximately $1,294,827.48. The trade was a 2.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 93,215 shares of company stock worth $666,835 in the last 90 days. 15.80% of the stock is owned by company insiders.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.